Skip to main content

Table 1 Study characteristics

From: Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis

Characteristic

No. of studies * (n = 444)

Percentage of studies

Year of publication

 

1990–1994

25

5.63

1995–1999

141

31.76

2000–2004

110

24.77

2005–2009

107

24.10

2010–2013

61

13.74

Geographic region

 

Asia

171

38.51

North America

118

26.58

Europe

108

24.32

Australasia

13

2.93

Multi-continent

12

2.70

Africa

11

2.48

South America

9

2.03

Not reported

2

0.45

Study design

 

Randomized clinical trial

429

96.62

Cohort study

9

2.03

Non-randomized clinical trial

5

1.13

Controlled before–after study

1

0.23

Study conduct period

 

1990–1999

11

2.48

2000–2009

45

10.14

2010–2013

8

1.80

Not reported

380

85.59

Duration of follow-up **

 

0 to ≤6

13

2.93

>6 to ≤12

9

2.03

>12 to ≤24

319

71.85

>24 to ≤48

52

11.71

>48 to ≤72

14

3.15

>72 to ≤1 week

12

2.70

>1 week

3

0.68

Not reported

22

4.95

Interventions examined: frequency ***

  

Serotonin antagonists Reported as administered alone (administered with dexamethasone)

Ondansetron

336 (46)

75.68 (10.36)

Granisetron

57 (15)

12.84 (3.38)

Tropisetron

35 (2)

7.88 (0.45)

Dolasetron

33 (3)

7.43 (0.68)

Palonosetron

14 (3)

3.15 (0.68)

Ramosetron

10 (1)

2.25 (0.23)

Comparator antiemetics

Butyrophenone

72

16.22

Benzamide

72

16.22

Dexamethasone

40

9.01

Phenothiazine

13

2.93

Antihistamine

11

2.48

NK-1

5

1.13

Anticholinergic

2

0.45

Serotonin antagonists given with other antiemetic

Serotonin antagonist + dexamethasone

70

15.77

Serotonin antagonist + butyrophenone

15

3.38

Serotonin antagonist + benzamide

5

1.13

Serotonin antagonist + antihistamine

3

0.68

Serotonin antagonist + NK-1

2

0.45

Serotonin antagonist + phenothiazine

2

0.45

Placebo or no treatment

  
 

293

65.99

Outcomes examined: frequency ****

  

Vomiting

347

78.15

Nausea

308

69.40

PONV

268

60.36

Setting

 

Not reported

270

60.81

Hospital

113

25.45

Multi-center

31

6.98

Medical center

30

6.76

  1. * Includes unpublished data; ** Duration is in hours unless otherwise noted; *** Multiple interventions and comparators examined across the studies; **** Multiple interventions and outcomes reported per study
  2. NK-1 neurokinin 1 receptor antagonist, PONV postoperative nausea and vomiting
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us